INDEMNIFICATION AGREEMENTIndemnification Agreement • April 2nd, 2021 • Rain Therapeutics Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of __________ by and between Rain Therapeutics Inc., a Delaware corporation (the “Company”), and __________ (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company.
RAIN THERAPEUTICS INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 2, 2020Investors’ Rights Agreement • April 2nd, 2021 • Rain Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 2, 2020, by and among Rain Therapeutics Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A attached hereto, (each, an “Investor,” and collectively, the “Investors”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 2nd, 2021 • Rain Therapeutics Inc. • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of September 10, 2020 (the “Effective Date”), by and between Rain Therapeutics Inc. (the “Company”) and Robert Doebele (“Executive”).
OFFICE LEASE AGREEMENT (MULTI-TENANT, FULL-SERVICE GROSS, CALIFORNIA) between as Landlord and Rain Therapeutics, Inc. as TenantOffice Lease Agreement • April 2nd, 2021 • Rain Therapeutics Inc. • Pharmaceutical preparations
This Office Lease Agreement (this “Lease”) is made as of the Lease Date set forth in the Basic Lease Information, by and between the Landlord identified in the Basic Lease Information (“Landlord”), and the Tenant identified in the Basic Lease Information (“Tenant”). Landlord and Tenant hereby agree as follows:
LICENSE AGREEMENT BETWEEN DAIICHI SANKYO COMPANY, LIMITED AND RAIN THERAPEUTICS INC.License Agreement • April 2nd, 2021 • Rain Therapeutics Inc. • Pharmaceutical preparations • New York
Rain shall [***] (and in any event within [***] after achievement of such milestone event) notify Daiichi Sankyo in writing of the achievement of any such milestone event. After receipt of such notice from Rain, Daiichi Sankyo shall issue Rain an invoice for the amount of the corresponding milestone payment. Rain shall pay Daiichi Sankyo within [***] after receipt of an invoice therefor from Daiichi Sankyo. If at the time any given milestone payment set forth in this Section 5.2 is due [***] and one or more preceding milestone payments for antecedent milestone events [***] have not been paid, then such unpaid precedent milestone payments shall be paid at such time as well. Notwithstanding the foregoing, [***], then, milestone event a) and b) are achieved and milestone payments for milestone event a) and b) shall become due. Rain shall notify Daiichi Sankyo in writing (i) [***] after the achievement of such milestone event (“First Notice”) and (ii) on [***] (“Second Notice”). Daiichi Sa
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Intellectual Property License Agreement • April 2nd, 2021 • Rain Therapeutics Inc. • Pharmaceutical preparations • Pennsylvania
This Intellectual Property License Agreement (this “Agreement”) includes this Signature Page and all of the attached Terms and Conditions and Exhibits, as applicable. This Agreement is between Drexel University, a Pennsylvania non-profit corporation (“Drexel”), and Rain Therapeutics Inc., a Delaware corporation (“Company”). This Agreement is being signed on July 30, 2020 (the “Execution Date”). This Agreement will become effective on July 30, 2020 (the “Effective Date”).
